Tatva Chintan Pharma IPO subscribed 4.51 times on first day of subscription The portion meant for qualified institutional buyers (QIBs) was subscribed 50 per cent, while the non-institutional investors' category received 1.14 times subscription and those for retail individual investors (RIIs) 8.24 times, according to an update on NSE. https://ift.tt/eA8V8J
Disastrous to administer vax to kids without trials: HC The court was informed by the Centre that clinical trials for the vaccines for children under 18 years are going on and on the verge of completion and that a policy will be formed by the government and children will be vaccinated when experts give permission. https://ift.tt/eA8V8J
Delta variant responsible for breakthrough infections: ICMR The study, the largest and first nation-wide study of post-vaccination breakthrough infections from India, said its analysis shows that the vaccination does provide reduction in hospital admission and mortality. https://ift.tt/eA8V8J
Centre buying Covishield at 215, Covaxin at 225 "We are on path to achieving the target of 50 crore doses by July 31, this is crucial towards meeting our target coverage by end of this year," the senior official said. https://ift.tt/eA8V8J